Walleye Capital LLC Neurocrine Biosciences Inc Call Options Transaction History

Walleye Capital LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $676,022 - $903,585	-5,900 Reduced 96.72%	200 $23,000
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $2.38 Million - $2.61 Million	-18,200 Reduced 74.9%	6,100 $839,000
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $3.17 Million - $3.49 Million	24,300 New	24,300 $3.35 Million
Q2 2020 Aug 14, 2020	SELL	$85.09 - $130.36 $204,216 - $312,864	-2,400 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $1.19 Million - $1.8 Million	-15,800 Reduced 86.81%	2,400 $208,000
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $1.98 Million - $2.7 Million	-22,800 Reduced 55.61%	18,200 $1.96 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $100,583 - $121,800	1,200 Added 3.02%	41,000 $3.7 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $1.29 Million - $1.62 Million	17,800 Added 80.91%	39,800 $3.36 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $1.52 Million - $2.01 Million	22,000 New	22,000 $1.94 Million

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.